EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Understanding Drug Exposure and Trichuris trichiura Cure Rates: A Pharmacometric Approach for Albendazole-Ivermectin Co-medication in Tanzania and Côte d’Ivoire

Veshni Pillay-Fuentes Lorente, Jacinta N Nwogu-Attah, Britta Steffens iD, Dominic Bräm iD, Viviane Sprecher, Daniela Hofmann, Michael Buettcher, Goonaseelan Pillai, Samer Mouksassi, Jean Coulibaly, Marc Pfister, Jennifer Keiser iD

Drugs in R&D · 2024

DOI: 10.1007/s40268-024-00476-4 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Drugs in R&D, 2024. Verfasst von Veshni Pillay-Fuentes Lorente und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Hauptthemen laut MEDLINE: Albendazole, Drug Therapy, Combination, Ivermectin, Trichuriasis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bill and Melinda Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Trichuriasis caused by the human whipworm Trichuris trichiura poses a significant public health concern. Albendazole-ivermectin co-medication is currently the most effective treatment. Studies conducted in Tanzania and Côte d'Ivoire unveiled differences in efficacy for albendazole-ivermectin combination therapy in both countries. A pharmacometrics approach was used to assess co-medication and study population effects on the pharmacokinetics of the two main metabolites of albendazole. An exploratory exposure-efficacy analysis was also carried out to investigate relationships between exposure measures and the egg reduction rate. METHODS: Pharmacokinetic data from studies in Tanzania and Côte d'Ivoire in adolescents (aged 12-19 years) were included in the pharmacometric analysis. Participants received a single dose of either albendazole 400 mg alone or in combination with ivermectin 200 µg/kg. A pharmacometric analysis was performed to investigate the potential effects of the study population and co-administered ivermectin on the apparent clearance of the metabolites of albendazole. Non-linear mixed-effects modeling was conducted with MonolixSuite 2023R1. The pharmacokinetic exposure measures derived from simulations with individual model parameters were used in the exploratory-exposure response analysis. RESULTS: Pharmacokinetic profiles were best described by a two-compartment model for albendazole sulfoxide and a one-compartment model for albendazole sulfone, with a transit compartment and linear elimination. While no co-medication effect was found, apparent clearance of albendazole sulfoxide (albendazole sulfone) in the Tanzanian study population was 75% (46%) higher than that in the Côte d'Ivoire study population. Exposure-efficacy response analyses indicated that peak concentration and the time-above-exposure threshold were associated with the egg reduction rate. CONCLUSIONS: Study population but not co-administered ivermectin showed an effect on apparent clearance of albendazole sulfoxide and albendazole sulfone. Polymorphisms in drug-metabolizing enzymes and host-parasite interaction may explain this result. Difference in drug exposure did not explain the disparate efficacy responses in Tanzania and Côte d'Ivoire. Peak concentration and time-above-threshold were exposure measures associated with the egg reduction rate. Further studies evaluating genetic and resistance patterns in various regions in Africa are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbendazoleDrug Therapy, CombinationIvermectinTrichuriasisTrichurisAdolescentAnimalsChildFemaleHumansMaleYoung AdultAnthelminticsCote d'IvoireTanzania

Substanzen

AlbendazoleAnthelminticsIvermectin

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
  • APT-Africa Fellowship Program, c/o Pharmacometrics Africa NPC, Groote Schuur Hospital, Cape Town, South Africa.
  • APT-Africa Fellowship Program, c/o Pharmacometrics Africa NPC, Groote Schuur Hospital, Cape Town, South Africa. nwogu.jacinta@lcu.edu.ng.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Lead City University, Off Oba Otudeko Avenue, Toll-Gate Area, Ibadan, 200255, Oyo, Nigeria. nwogu.jacinta@lcu.edu.ng.
  • Pediatric Pharmacology and Pharmacometrics, University of Basel Children's Hospital (UKBB), Basel, Switzerland.
  • Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Allschwil Switzerland, University of Basel, Basel, Switzerland.

ORCID-Profile: Britta Steffens, Dominic Bräm, Jennifer Keiser

Förderung

  • Bill and Melinda Gates Foundation

Zitieren

APA

Pillay-Fuentes Lorente, V., Nwogu-Attah, J. N., Steffens, B., Bräm, D., Sprecher, V., Hofmann, D., Buettcher, M., Pillai, G., Mouksassi, S., Coulibaly, J., Pfister, M., & Keiser, J. (2024). Understanding Drug Exposure and Trichuris trichiura Cure Rates: A Pharmacometric Approach for Albendazole-Ivermectin Co-medication in Tanzania and Côte d’Ivoire. Drugs in R&D. https://doi.org/10.1007/s40268-024-00476-4

Vancouver

Pillay-Fuentes Lorente V, Nwogu-Attah JN, Steffens B, Bräm D, Sprecher V, Hofmann D, et al. Understanding Drug Exposure and Trichuris trichiura Cure Rates: A Pharmacometric Approach for Albendazole-Ivermectin Co-medication in Tanzania and Côte d’Ivoire. Drugs in R&D. 2024. doi:10.1007/s40268-024-00476-4

BibTeX
@article{PillayFuentesLorente2024,
  author = {Pillay-Fuentes Lorente, Veshni and Nwogu-Attah, Jacinta N and Steffens, Britta and Bräm, Dominic and Sprecher, Viviane and Hofmann, Daniela and Buettcher, Michael and Pillai, Goonaseelan and Mouksassi, Samer and Coulibaly, Jean and Pfister, Marc and Keiser, Jennifer},
  title = {Understanding Drug Exposure and Trichuris trichiura Cure Rates: A Pharmacometric Approach for Albendazole-Ivermectin Co-medication in Tanzania and Côte d’Ivoire},
  journal = {Drugs in R&D},
  year = {2024},
  doi = {10.1007/s40268-024-00476-4}
}
Kostenlos starten →